RxDoctor Payments Data

Patricia Sauter

Women's Health · Bradenton, FLNPI 1821201393

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 190 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 12 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,253, 3.4 times the $371 reported in 2021. Among women's health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$3,688in general payments, 2019–2025

Across 190 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$805
  • Alkermes, Inc.$770
  • Johnson & Johnson$679
  • Teva Pharmaceuticals USA, Inc.$392
  • AbbVie$389
  • Otsuka America Pharmaceutical, Inc.$247
  • plus $406 from 6 others

What the payments were for

  • Food & beverage$3,688100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,688 in reported general payments places this provider in the 95th percentile of 308 women's health providers in Florida.

See all women's health providers in Florida

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate36$301,459
AustedoDeutetrabenazine24$135,008
Invega SustennaPaliperidone Palmitate31$111,471
VraylarCariprazine Hcl33$48,029
Clozapine512$44,413
Abilify MaintenaAripiprazole13$40,106
Clozapine OdtClozapine78$36,234
CaplytaLumateperone Tosylate15$25,299
TrintellixVortioxetine Hydrobromide13$11,194
Aripiprazole168$10,523
Ziprasidone Hcl45$8,317
ClozarilClozapine13$5,602
Fluphenazine Hcl25$3,790
Quetiapine Fumarate201$3,644
Olanzapine87$2,524

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$805$301,45936 claims
Teva Pharmaceuticals USA, Inc.Austedo$392$135,00824 claims
Johnson & JohnsonInvega Sustenna$679$111,47131 claims
AbbVieVraylar$389$48,02933 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$247$40,10613 claims
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta$94$25,29915 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 308 women's health providers in Florida.

Other women's health in Bradenton

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →